IBS Medications, Medical Foods and Fecal Microbiota Transplantation (FMT)

ZAXINE® (rifaximin) - Now Indicated in Canada for Patients with Irritable Bowel Syndrome with Diarrhea (IBS-D) NEWS PROVIDED BY Lupin Pharma Canada Dec 06, 2018, 07:00 ET BSE: 500257 NSE: LUPIN REUTERS: LUPIN.BO BLOOMBERG: LPCIN MONTREAL, Dec. 6, 2018 /PRNewswire/ - Lupin Pharma Canada is pleased to announce the approval from Health Canada for…

VSL#3, a probiotic marketed for IBD and IBS, abruptly removed from the Canadian market. http://www.vsl3.ca

"Finch and Takeda pharmaceutical inked a global collaboration deal to jointly develop FIN-524. FIN-524 is a live biotherapeutic product made up of cultured bacteria strains that have been associated with positive clinical outcomes in irritable bowel disease (IBD). https://www.biospace.com/article/finch-therapeutics-raises-36-million-series-b-bringing-total-to-77-million/

For anyone interested in FMTs, there is these studies that has been completed ; https://www.ncbi.nlm.nih.gov/pubmed/29100842?dopt=Abstract and this one; https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0194904 some suggested reading; "10% Human" by Alanna Collen

I was researching stocks today and came across this; "4d Pharma's blautix showed efficacy in irritable bowel syndrome" https://www.streetwisereports.com/article/2018/10/10/this-biotech-is-harnessing-the-microbiomes-therapeutic-potential.html Has anyone had any experience with this product ?

If you have diarrhea symptoms, when do you take an anti-diarrheal such as imodium? At first go? After 5 BM's? Never?

The American College of Gastroenterology (ACG) annual meeting reported some observations from patients who were treated with Fecal Matter Transplantation (FMT) for an overgrowth of Clostridium Difficile (C Diff). C Diff is a very serious bowel infection that is difficult to resolve. It is usually caused by antibiotics. FMT has a greater than 90% cure rate for C Diff. However, two observations were made about patients who recovered from C Diff after FMT: 1) Postinfectious-IBS developed in 25% of those that received FMT for their C Diff. 2) Crohn's disease or Ulcerative Colitis patients were likely to have a flaring episode of their disease from the FMT treatment.…

Sebela Pharmaceuticals Inc. is pleased to announce that Motofen® is now available in pharmacies nationwide. Please check with your local pharmacy for availability. For more information on Motofen, please visit motofen.com. Important Safety Information INDICATIONS AND USAGE Motofen® (difenoxin and atropine sulfate tablets) is indicated as adjunctive therapy in the management of acute nonspecific diarrhea and acute exacerbations of chronic functional diarrhea. CONTRAINDICATIONS Motofen® is contraindicated in patients with diarr…

Motofen is coming soon in the US! Great news for people who were waiting for Motofen to return to the market for IBS-D and non-specific D. I just received a note from the Pharma who makes it: Sebela Pharmaceuticals Inc. is pleased to announce that the FDA has approved the reintroduction of Motofen® to the market. We are working closely with pharmacies nationwide to make sure Motofen is easily available. We anticipate full availability in late June or early July and will update you at that time. More info on Motofen here, http://www.motofen.com

A new update about the medication Motofen (http://www.motofen.com) for diarrhea was recently sent to me:

I would really like to hear from anyone who is taking or has tried Viberzi for IBS-D. What were your results?

Hi everyone, I've come across BPC-157 in my search for anything to help with Ulcerative colitis. I've read about a few other people using it to treat IBD, IBS, injuries, etc. It's turning out to be quite the little Wunderdrug according to some of the studies posted on this forum. Pubmed- Stable gastric pentadecapeptide BPC 157 heals rat colovesical fistula. Pubmed- Toxicity by NSAIDs. Counteraction by stable gastric pentadecapeptide BPC 157. Pubmed- Focus on Ulcerative Colitis: Stable Gastric Pentadecapeptide BPC 157. Pubmed- BPC 157 therapy to detriment sphincters failure-esophagitis-pancreatitis in rat and acute pancreatitis patients low sphincters pressure. …

An update about the medication Motofen for diarrhea. Motofen is the brand name for an anti-diarrheal medication, containing 1.0 mg difenoxin HCl and 0.025 mg atropine. This combination medication should not be confused with Lomotil because the active ingredients in the two medications are different compounds, except for the inclusion of atropine. Motofen is said to be approximately 2 to 4 times more effective in treating symptoms than Lomotil.

At Digestive Disease Week (DDW) in Chicago, I met with the new pharmaceutical (Sebela Pharmaceuticals) that will be marketing Motofen. Motofen is primarily used as an anti-diarrheal medication and has been on/off the market since 1978. Motofen contains difenoxin and is considered a Schedule IV medication which means it is unlikely to be habit forming; however, it needs to be managed very closely. Atropine is added to help the drug not become habit forming. The drug was recently acquired by Sebela and they are in the imminent process of marketing it. For some, this medication will work similar to Lomotil. You can read more about Motofen on its website, http:…